Becton, Dickinson and Stock Forecast for 2023 - 2025 - 2030
Updated on 09/26/2023
Becton, Dickinson and Stock Forecast and Price Target
Given the average yearlong price target of $275.00 provided by twelve prominent analysts over the past few months, there is a potential upside of approximately 3.09% from the last closing price in September, 2023 for Becton, Dickinson and's stock if it is reached. This estimation is based on a high estimate of $306.00 and a low estimate of $245.00. If you're interested in BDX stock, looking at its competitors might also be a good idea.
3.09% Upside
Becton, Dickinson and Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Becton, Dickinson and's Price has decreased by 2.83%, from $242.94 to $236.08. For next year, analysts predict Fair Value of $260.42, which would mean an increase of 10.31%. Over the next eight years, experts predict that Becton, Dickinson and's Fair Value will grow at a rate of 46.04%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
14
|
$552.32 | Buy/Sell | $333.19 | -27.58% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$160.26 | Buy/Sell | $179.95 | 12.63% |
| AVGO Stock Forecast | Broadcom Inc | Outperform |
7
|
$833.89 | Buy/Sell | $656.43 | -20.97% |
| ABBV Stock Forecast | AbbVie | Outperform |
10
|
$154.72 | Buy/Sell | $162.24 | 6.64% |
| AZN Stock Forecast | AstraZeneca PLC | Buy |
8
|
£11.14k | Buy/Sell | £153.20 | -98.60% |
Becton, Dickinson and Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Becton, Dickinson and's Revenue has grown by 9.14%, rising from $17.29B to $18.87B. For next year, analysts predict Revenue of $19.46B, which would mean an increase of 3.11%. Over the next eight years, experts predict that Becton, Dickinson and's Revenue will grow at a rate of 17.97%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABT Stock Forecast | Abbott Laboratories | Outperform |
10
|
$97.47 | Buy/Sell | $124.05 | 28.24% |
| DHR Stock Forecast | Danaher Corp | Outperform |
10
|
$252.04 | Buy/Sell | $304.24 | 20.81% |
| ISRG Stock Forecast | Intuitive Surgical Inc | Outperform |
13
|
$293.25 | Buy/Sell | $361.91 | -3.84% |
.jpg)
Becton, Dickinson and Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Becton, Dickinson and's Dividend per Share has grown, rising from $3.08 to $3.48 – a growth of 12.99%. In the next year, analysts believe that Dividend per Share will reach $4.06 – an increase of 16.67%. For the next eight years, the forecast is for Dividend per Share to grow by 33.87%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GE Stock Forecast | General Electric | Outperform |
7
|
$111.71 | Buy/Sell | $127.45 | -22.12% |
| BSX Stock Forecast | Boston Scientific Corp | Outperform |
15
|
$53.81 | Buy/Sell | $52.51 | -7.08% |
| GSK Stock Forecast | GSK | Outperform |
16
|
£1.53k | Buy/Sell | £16.95 | -98.95% |
Becton, Dickinson and Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last three years, Becton, Dickinson and's Free Cash Flow has seen a drop from $2.37B to $1.80B – a 24.32% decrease. In the next year, analysts believe that Free Cash Flow will reach $3.26B – an increase of 81.51%. For the next eight years, the forecast is for Free Cash Flow to grow by 133.55%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| EMR Stock Forecast | Emerson Electric | Outperform |
10
|
$98.10 | Buy/Sell | $104.16 | 7.03% |
| BAYN Stock Forecast | Bayer | Outperform |
7
|
46.32€ | Buy/Sell | 74.54€ | 63.00% |
| 6501 Stock Forecast | Hitachi | Buy |
18
|
¥6.56k | Buy/Sell | ¥0.00 | 29.65% |
Becton, Dickinson and Net Income Forecast for 2023 - 2025 - 2030
Becton, Dickinson and's Net Income has grown In the last three years, rising from $1.23B to $1.78B – a growth of 44.28%. In the next year, analysts believe that Net Income will reach $3.56B – an increase of 100.27%. For the next eight years, experts predict that Becton, Dickinson and's Net Income will grow at a rate of 157.18%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ECL Stock Forecast | Ecolab Inc | Outperform |
18
|
$172.18 | Buy/Sell | $164.25 | -4.17% |
| A Stock Forecast | Agilent Technologies | Outperform |
17
|
$111.94 | Buy/Sell | $141.56 | 48.74% |
| LONN Stock Forecast | Lonza Group Ltd | Outperform |
16
|
CHF457.90 | Buy/Sell | CHF756.46 | 71.98% |
Becton, Dickinson and EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Becton, Dickinson and's EBITDA has gone down from $5.20B to $4.85B – a 6.68% drop. For the next year, analysts predict that EBITDA will reach $5.40B – an increase of 11.30%. Over the next eight years, experts believe that Becton, Dickinson and's EBITDA will grow at a rate of 36.55%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALC Stock Forecast | Alcon | Outperform |
15
|
CHF66.18 | Buy/Sell | CHF0.00 | 30.51% |
| ILMN Stock Forecast | Illumina Inc | Outperform |
16
|
$131.41 | Buy/Sell | $254.08 | 89.86% |
| COLO B Stock Forecast | Coloplast A/S | Hold |
18
|
kr848.20 | Buy/Sell | kr1.05k | 21.43% |
Becton, Dickinson and EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Becton, Dickinson and's EBIT has fallen from $2.94B to $2.62B – a 10.97% decrease. In the next year, analysts predict that EBIT will jump to $4.47B – up 70.70% from the current level. Looking ahead to eight years, experts forecast that EBIT will grow by 120.28%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$37.50 | Buy/Sell | $60.73 | 54.67% |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.92k | Buy/Sell | ¥0.00 | 24.74% |
| LH Stock Forecast | Laboratory Corp of America Hol... | Outperform |
11
|
$208.43 | Buy/Sell | $278.38 | 31.94% |
Becton, Dickinson and EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Becton, Dickinson and's EPS has decreased by 2.83%, from $11.68 to $11.35. For next year, analysts predict EPS of $12.52, which would mean an increase of 10.31%. Over the next eight years, experts predict that Becton, Dickinson and's EPS will grow at a rate of 46.04%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 7751 Stock Forecast | Canon | Hold |
18
|
¥2.86k | Buy/Sell | ¥0.00 | 16.95% |
| FRE Stock Forecast | Fresenius SE & Co. KGaA | Outperform |
18
|
30.26€ | Buy/Sell | 35.23€ | 7.40% |
| HOLX Stock Forecast | Hologic Inc | Outperform |
8
|
$84.06 | Buy/Sell | $79.86 | -1.86% |
Site Navigation
.jpg)